

Arthur J A T Braat

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6618419/publications.pdf>

Version: 2024-02-01

64
papers

1,272
citations

361296

20
h-index

395590

33
g-index

65
all docs

65
docs citations

65
times ranked

1079
citing authors

#	ARTICLE	IF	CITATIONS
1	Prospective Validation of Gallium-68 Prostate Specific Membrane Antigen-Positron Emission Tomography/Computerized Tomography for Primary Staging of Prostate Cancer. <i>Journal of Urology</i> , 2020, 203, 537-545.	0.2	79
2	⁹⁰ Y Hepatic Radioembolization: An Update on Current Practice and Recent Developments. <i>Journal of Nuclear Medicine</i> , 2015, 56, 1079-1087.	2.8	77
3	Radioembolization with ⁹⁰ Y Resin Microspheres of Neuroendocrine Liver Metastases: International Multicenter Study on Efficacy and Toxicity. <i>CardioVascular and Interventional Radiology</i> , 2019, 42, 413-425.	0.9	70
4	The physics of radioembolization. <i>EJNMMI Physics</i> , 2018, 5, 22.	1.3	65
5	Holmium-166 Microsphere Radioembolization of Hepatic Malignancies. <i>Seminars in Nuclear Medicine</i> , 2019, 49, 237-243.	2.5	64
6	The superior predictive value of ¹⁶⁶ Ho-scout compared with ^{99m} Tc-macroaggregated albumin prior to ¹⁶⁶ Ho-microspheres radioembolization in patients with liver metastases. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 798-806.	3.3	62
7	Impact of external cooling with icepacks on ⁶⁸ Ga-PSMA uptake in salivary glands. <i>EJNMMI Research</i> , 2018, 8, 56.	1.1	54
8	Safety analysis of holmium-166 microsphere scout dose imaging during radioembolisation work-up: A cohort study. <i>European Radiology</i> , 2018, 28, 920-928.	2.3	53
9	Personalised radioembolization improves outcomes in refractory intra-hepatic cholangiocarcinoma: a multicenter study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 2270-2279.	3.3	52
10	Yttrium-90 Radioembolization in Intrahepatic Cholangiocarcinoma: A Multicenter Retrospective Analysis. <i>Journal of Vascular and Interventional Radiology</i> , 2020, 31, 1035-1043.e2.	0.2	49
11	Additional holmium-166 radioembolisation after lutetium-177-dotatate in patients with neuroendocrine tumour liver metastases (HEPAR PLUS): a single-centre, single-arm, open-label, phase 2 study. <i>Lancet Oncology</i> , The, 2020, 21, 561-570.	5.1	48
12	⁶⁸ Ga-PSMA PET/CT in radioactive iodine-refractory differentiated thyroid cancer and first treatment results with ¹⁷⁷ Lu-PSMA-617. <i>EJNMMI Research</i> , 2020, 10, 18.	1.1	46
13	Radioembolization with ⁹⁰ Y Resin Microspheres of Neuroendocrine Liver Metastases After Initial Peptide Receptor Radionuclide Therapy. <i>CardioVascular and Interventional Radiology</i> , 2020, 43, 246-253.	0.9	37
14	Dose-Response and Dose-Toxicity Relationships for Glass ⁹⁰ Y Radioembolization in Patients with Liver Metastases from Colorectal Cancer. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1616-1623.	2.8	36
15	Additional hepatic ¹⁶⁶ Ho-radioembolization in patients with neuroendocrine tumours treated with ¹⁷⁷ Lu-DOTATATE; a single center, interventional, non-randomized, non-comparative, open label, phase II study (HEPAR PLUS trial). <i>BMC Gastroenterology</i> , 2018, 18, 84.	0.8	32
16	Dose-Effect Relationships of ¹⁶⁶ Ho Radioembolization in Colorectal Cancer. <i>Journal of Nuclear Medicine</i> , 2021, 62, 272-279.	2.8	32
17	Radioembolisation with ⁹⁰ Y microspheres for neuroendocrine liver metastases: an institutional case series, systematic review and meta-analysis. <i>Hpb</i> , 2019, 21, 773-783.	0.1	31
18	Intra-arterial versus standard intravenous administration of lutetium-177-DOTA-octreotate in patients with NET liver metastases: study protocol for a multicenter, randomized controlled trial (LUTIA) <i>Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 57</i>		

#	ARTICLE	IF	CITATIONS
19	Holmium-166 Radioembolization: Current Status and Future Prospective. CardioVascular and Interventional Radiology, 2022, 45, 1634-1645.	0.9	26
20	Hepatic Radioembolization as a Bridge to Liver Surgery. Frontiers in Oncology, 2014, 4, 199.	1.3	23
21	First Experience With 177Lu-PSMA-617 Therapy for Advanced Prostate Cancer in the Netherlands. Clinical Nuclear Medicine, 2019, 44, 446-451.	0.7	22
22	Will 177Lu-DOTATATE Treatment Become More Effective in Salvage Meningioma Patients, When Boosting Somatostatin Receptor Saturation? A Promising Case on Intra-arterial Administration. CardioVascular and Interventional Radiology, 2019, 42, 1649-1652.	0.9	17
23	Adequate SIRT activity dose is as important as adequate chemotherapy dose. Lancet Oncology, The, 2017, 18, e636.	5.1	16
24	Current Status and Future Direction of Hepatic Radioembolisation. Clinical Oncology, 2021, 33, 106-116.	0.6	16
25	First experiences with 177Lu-PSMA-617 therapy for recurrent or metastatic salivary gland cancer. EJNMMI Research, 2021, 11, 126.	1.1	15
26	Feasibility of imaging ⁹⁰ Y microspheres at diagnostic activity levels for hepatic radioembolization treatment planning. Medical Physics, 2020, 47, 1105-1114.	1.6	13
27	Use of an anti-reflux catheter to improve tumor targeting for holmium-166 radioembolization—a prospective, within-patient randomized study. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 1658-1668.	3.3	13
28	Intraarterial Administration Boosts ¹⁷⁷ Lu-HA-DOTATATE Accumulation in Salvage Meningioma Patients. Journal of Nuclear Medicine, 2022, 63, 406-409.	2.8	13
29	Simultaneous 166Ho/99mTc dual-isotope SPECT with Monte Carlo-based downscatter correction for automatic liver dosimetry in radioembolization. EJNMMI Physics, 2020, 7, 13.	1.3	12
30	Cardiac sympathetic innervation and cardiac resynchronization therapy. Heart Failure Reviews, 2014, 19, 567-573.	1.7	11
31	Safety and Efficacy of ¹⁶⁶ Ho Radioembolization in Hepatocellular Carcinoma: The HEPAR Primary Study. Journal of Nuclear Medicine, 2022, 63, 1891-1898.	2.8	11
32	The value of yttrium-90 PET/CT after hepatic radioembolization: a pictorial essay. Clinical and Translational Imaging, 2019, 7, 303-312.	1.1	10
33	Indocyanine green versus technetium-99m with blue dye for sentinel lymph node detection in early-stage cervical cancer: A systematic review and meta-analysis. Cancer Reports, 2022, 5, e1401.	0.6	10
34	⁹⁰ Y radioembolization in the treatment of neuroendocrine neoplasms: Results of an international multicenter retrospective study.. Journal of Nuclear Medicine, 2021, , jnumed.121.262561.	2.8	10
35	Quantitative 166Ho-microspheres SPECT derived from a dual-isotope acquisition with 99mTc-colloid is clinically feasible. EJNMMI Physics, 2020, 7, 48.	1.3	10
36	Dose-response relationship after yttrium-90-radioembolization with glass microspheres in patients with neuroendocrine tumor liver metastases. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 1700-1710.	3.3	10

#	ARTICLE	IF	CITATIONS
37	Baseline Imaging Derived Predictive Factors of Response Following [177Lu]Lu-PSMA-617 Therapy in Salvage Metastatic Castration-Resistant Prostate Cancer: A Lesion- and Patient-Based Analysis. <i>Biomedicines</i> , 2022, 10, 1575.	1.4	10
38	Intra-Arterial Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumor Liver Metastases. <i>Digestive Disease Interventions</i> , 2019, 03, 081-090.	0.3	9
39	Gamma camera characterization at high holmium-166 activity in liver radioembolization. <i>EJNMMI Physics</i> , 2021, 8, 22.	1.3	9
40	Lutetium-177-PSMA therapy for prostate cancer patientsâ€”aÂbrief overview of the literature. <i>Tijdschrift Voor Urologie</i> , 2020, 10, 141-146.	0.1	8
41	Evaluation of the Safety and Feasibility of Same-Day Holmium-166 -Radioembolization Simulation and Treatment of Hepatic Metastases. <i>Journal of Vascular and Interventional Radiology</i> , 2020, 31, 1593-1599.	0.2	6
42	A compact and mobile hybrid C-arm scanner for simultaneous nuclear and fluoroscopic image guidance. <i>European Radiology</i> , 2022, 32, 517-523.	2.3	6
43	The feasibility of folate receptor alpha- and HER2-targeted intraoperative fluorescence-guided cytoreductive surgery in women with epithelial ovarian cancer: A systematic review. <i>Gynecologic Oncology</i> , 2021, 162, 517-525.	0.6	5
44	Lung Dose Measured on Postradioembolization ⁹⁰ Y PET/CT and Incidence of Radiation Pneumonitis. <i>Journal of Nuclear Medicine</i> , 2022, 63, 1075-1080.	2.8	5
45	Gastrointestinal stromal tumour detection with somatostatin receptor imaging, 68Ga-HA-DOTATATE PETâ€”CT. <i>Lancet Oncology</i> , The, 2017, 18, e185.	5.1	4
46	The Efficacy of Coil Embolization to Obtain Intrahepatic Redistribution in Radioembolization: Qualitative and Quantitative Analyses. <i>CardioVascular and Interventional Radiology</i> , 2020, 43, 391-401.	0.9	4
47	[18F]FDG and [18F]FES positron emission tomography for disease monitoring and assessment of anti-hormonal treatment eligibility in granulosa cell tumors of the ovary. <i>Oncotarget</i> , 2021, 12, 665-673.	0.8	4
48	A Rapid and Safe Infusion Protocol for ¹⁷⁷ Lu Peptide Receptor Radionuclide Therapy. <i>Journal of Nuclear Medicine</i> , 2021, 62, 816-822.	2.8	4
49	Gallium-68-somatostatin receptor PET/CT parameters as potential prognosticators for clinical time to progression after peptide receptor radionuclide therapy: a cohort study. <i>European Journal of Hybrid Imaging</i> , 2021, 5, 22.	0.6	4
50	Toxicity and dosimetry in SORAMIC study. <i>Journal of Hepatology</i> , 2020, 73, 734-735.	1.8	3
51	Inflammatory markers and long term hematotoxicity of holmium-166-radioembolization in liver-dominant metastatic neuroendocrine tumors after initial peptide receptor radionuclide therapy. <i>EJNMMI Research</i> , 2022, 12, 7.	1.1	3
52	Value of routine cytokeratin immunohistochemistry in detecting low volume disease in cervical cancer. <i>Gynecologic Oncology</i> , 2022, 165, 257-263.	0.6	3
53	The Evolving Role of Radioembolization in the Treatment of Neuroendocrine Liver Metastases. <i>Cancers</i> , 2022, 14, 3415.	1.7	3
54	Estimation of lung shunt fraction from simultaneous fluoroscopic and nuclear images. <i>Physics in Medicine and Biology</i> , 2017, 62, 8210-8225.	1.6	2

#	ARTICLE	IF	CITATIONS
55	No Need for Prophylactic Abdominal Ice Packing During Radioembolization. CardioVascular and Interventional Radiology, 2018, 41, 200-201.	0.9	2
56	Competition (â€˜Stealâ€™ Phenomenon) between [68Ga]Ga-PSMA-11 Uptake in Prostate Tumor Tissue Versus Healthy Tissue. Pharmaceutics, 2021, 13, 699.	2.0	2
57	166Holmiumâ€™99mTechnetium dual-isotope imaging: scatter compensation and automatic healthy-liver segmentation for 166Holmium radioembolization dosimetry. EJNMMI Physics, 2022, 9, 30.	1.3	2
58	Verification Study of Residual Activity Measurements After Yttrium-90 Radioembolization with Glass Microspheres. CardioVascular and Interventional Radiology, 2020, 43, 1378-1383.	0.9	1
59	Personalized Dosimetry: The Way to Limit Hepatotoxicity. Journal of Vascular and Interventional Radiology, 2020, 31, 515-516.	0.2	1
60	Holmium-166 Radioembolization in NET Patients. , 2021, , 241-250.		0
61	Yttrium-90 SIRT in NET. , 2021, , 231-239.		0
62	Holmium-166 Radioembolization. Digestive Disease Interventions, 0, 05, .	0.3	0
63	99mTc-HDP bone scintigraphy confirming parathyroid hormone-related peptide paraneoplastic syndrome in metastatic breast cancer. Lancet Oncology, The, 2021, 22, e216.	5.1	0
64	Challenges in Von Hippelâ€™Lindauâ€™s disease: PRRT in patients on hemodialysis. Endocrinology, Diabetes and Metabolism Case Reports, 2022, 2022, .	0.2	0